Huisman C, van der Straaten H M, Canninga-van Dijk M R, Fijnheer R, Verdonck L F
Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands.
Bone Marrow Transplant. 2006 Oct;38(8):561-6. doi: 10.1038/sj.bmt.1705484. Epub 2006 Sep 4.
Lung injury limits the success of allogeneic stem cell transplantation (SCT). The overall incidence varies from 30 to 50% and non-infectious causes occur in one-third to one-half of these. We reviewed pulmonary complications in 369 consecutive patients who received a partially T-cell-depleted myeloablative allogeneic hematopoietic SCT at our institution between 1993 and 2003. All patients were treated uniformly with cyclophosphamide followed by total body irradiation. Control subjects were matched on sex, underlying diagnosis, age, type of transplantation and cytomegalovirus (CMV)-serostatus. Sixty-one patients (16.5%) developed pulmonary complications. Twenty-one patients (5.7%) developed infectious pneumonia. Forty patients developed non-infectious complications which were further subclassified as bronchiolitis obliterans (3.5%), bronchiolitis obliterans-organizing pneumonia (0.5%), diffuse alveolar hemorrhage (0.8%), idiopathic pneumonia syndrome (5.5%) or mixed etiology (0.5%). Acute graft-versus-host disease (GVHD) > or =grade II was significantly more common in pulmonary patients than in the controls (36/61 versus 22/61 patients, P=0.02). There was no significant difference in the incidence of chronic GVHD (P=0.09). CMV reactivation was significantly more frequent in patients with lung injury (P=0.02). Median survival was 41 weeks for the pulmonary patients and 350 weeks for the controls (P=0.001). Altogether, the incidence of pulmonary complications is low after T-cell-depleted SCT and is associated with acute GVHD and CMV reactivation.
肺损伤限制了异基因干细胞移植(SCT)的成功率。其总体发生率在30%至50%之间,其中三分之一至一半是由非感染性原因引起的。我们回顾了1993年至2003年间在我们机构接受部分T细胞清除的清髓性异基因造血干细胞移植的369例连续患者的肺部并发症情况。所有患者均接受环磷酰胺治疗,随后进行全身照射。对照对象在性别、基础诊断、年龄、移植类型和巨细胞病毒(CMV)血清学状态方面进行了匹配。61例患者(16.5%)出现了肺部并发症。21例患者(5.7%)发生了感染性肺炎。40例患者出现了非感染性并发症,进一步细分为闭塞性细支气管炎(3.5%)、闭塞性细支气管炎伴机化性肺炎(0.5%)、弥漫性肺泡出血(0.8%)、特发性肺炎综合征(5.5%)或混合病因(0.5%)。肺部并发症患者中急性移植物抗宿主病(GVHD)≥Ⅱ级明显比对照组更常见(36/61对22/61例患者,P = 0.02)。慢性GVHD的发生率没有显著差异(P = 0.09)。肺损伤患者中CMV再激活明显更频繁(P = 0.02)。肺部并发症患者的中位生存期为41周,对照组为350周(P = 0.001)。总之,T细胞清除后的干细胞移植后肺部并发症的发生率较低,且与急性GVHD和CMV再激活有关。